Free Newsletter
Sanofi asks for Zentiva extension, again
Like an army besieging the castle keep, Sanofi-Aventis stands waiting...waiting...hoping to crack its quarry's defenses. The drugmaker has asked yet again to extend its offer for Czech generics firm Zentiva. The current offer expires Friday.
But barring a sweetened offer, it's tough to see just how Sanofi might prevail. Earlier this month, Zentiva repeated its contempt for the 1,050 crown-a-share bid, saying it undervalues the company. And as BNet notes, Sanofi seems to need Zentiva more than Zentiva needs Sanofi. The bigger company has its share of the troubles plaguing pharma, while Zentiva is on a growth curve.
- get the news from EasyBourse
- read the BNet item
Related Articles:
Zentiva spurns Sanofi's buyout offer
Zentiva calls meeting on Sanofi bid
Sanofi launches $1.92B Zentiva offer
PPF leaves Zentiva to Sanofi
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: